封面
市场调查报告书
商品编码
1378733

2023-2028 年偏头痛药物市场报告(依治疗类型、药物类型、给药途径、配销通路和地区)

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2023-2028

出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年全球偏头痛药物市场规模达到40亿美元。展望未来, IMARC Group预计到2028年市场规模将达到54亿美元,2022-2028年复合年增长率(CAGR)为5.1%。

偏头痛是一种神经系统疾病,会导致前额、头部侧面或眼睛周围出现单侧或搏动性疼痛。疼痛常伴随自主神经症状,如噁心、呕吐、畏光、畏声等。偏头痛通常透过检查患者的病史和症状、进行血液检查、磁振造影 (MRI) 和电脑断层扫描 (CT) 扫描来诊断。目前,非处方药(OTC)和处方注射剂可缓解症状并降低偏头痛发作的频率和严重程度。这些药物可以定期服用,也可以在慢性疼痛发作或恶化期间服用。

偏头痛的盛行率和诊断率显着上升是推动市场成长的关键因素之一。除此之外,偏头痛药物报销政策的改善以及精准药物需求的不断增加也促进了市场的成长。此外,用于治疗偏头痛的电神经刺激装置的需求不断增长,以及处于后期研发阶段且具有更高临床疗效的新类别药物的预期批准,例如降钙素基因相关胜肽(CGRP)单株抗体的引入,也推动了市场的成长。然而,由于社交距离规范,偏头痛的临床就诊和程序治疗的减少影响了市场的成长。

本报告回答的关键问题:

  • 迄今为止,全球偏头痛药物市场表现如何,未来几年将如何表现?
  • COVID-19 对全球偏头痛药物市场有何影响?
  • 主要区域市场有哪些?
  • 根据治疗类型的市场划分是怎样的?
  • 根据药物类型分類的市场是怎么样的?
  • 根据给药途径,市场的分化为何?
  • 基于配销通路的市场区隔是什么?
  • 产业价值链的各个阶段是什么?
  • 该行业的关键驱动因素和挑战是什么?
  • 全球偏头痛药物市场的结构如何?谁是主要参与者?
  • 产业竞争程度如何?

目录

第一章:前言

第 2 章:范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章:执行摘要

第 4 章:简介

  • 概述
  • 主要行业趋势

第 5 章:全球偏头痛药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章:按治疗类型分類的市场区隔

  • 流产治疗
    • 市场走向
    • 市场预测
  • 预防性治疗
    • 市场走向
    • 市场预测

第 7 章:按药物类型分類的市场细分

  • 曲普坦类
    • 市场走向
    • 市场预测
  • 麦角生物碱
    • 市场走向
    • 市场预测
  • 非类固醇抗发炎药
    • 市场走向
    • 市场预测
  • 乙酰胆碱抑制剂/神经毒素
    • 市场走向
    • 市场预测
  • 迪坦斯
    • 市场走向
    • 市场预测
  • CGRP 单株抗体
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章:按管理途径分類的市场

  • 口服
    • 市场走向
    • 市场预测
  • 可注射
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章:按配销通路分類的市场区隔

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章:按地区分類的市场细分

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太地区
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 11 章:SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章:价值链分析

第 13 章:波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章:价格分析

第15章:竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Allergan Plc (Abbvie Inc.)
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
Product Code: SR112023A2543

Abstract

The global migraine drugs market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 5.1% during 2022-2028.

Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient's medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.

A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global migraine drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type, drug type, route of administration and distribution channel.

Breakup by Treatment Type:

Abortive Treatment

Preventive Treatment

Breakup by Drug Type:

Triptans

Ergot Alkaloids

NSAIDs

Acetylcholine Inhibitors/ Neurotoxins

Ditans

CGRP mAbs

Others

Breakup by Route of Administration:

Oral

Injectable

Others

Breakup by Distribution Channel:

Hospital-Based Pharmacies

Retail Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:

  • How has the global migraine drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global migraine drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global migraine drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2022
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players